

1 **Blood biomarkers-defined subgroups show heterogeneity in post-acute**  
2 **COVID-19 syndrome: a rationale for precision medicine.**

3 **Benjamin Charvet<sup>1</sup>, Alexandre Lucas<sup>2</sup>, Justine Pierquin<sup>1</sup>, Joanna Brunel<sup>1</sup>, Steven Fried<sup>3</sup>,**  
4 **Corinne Bernis<sup>3</sup>, Zachary S. Orban<sup>3</sup>, Millenia Jimenez<sup>3</sup>, Barbara A. Hanson<sup>3</sup>, Lavanya**  
5 **Visvabharathy<sup>3</sup>, Igor J. Koralnik<sup>3</sup>, Hervé Perron<sup>1\*</sup>, PhD.**

6 <sup>1</sup>Geneuro-Innovation, Bioparc Laennec, 69008, Lyon, France.

7 <sup>2</sup> We-Met platform, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), plateau We-Met,  
8 Inserm UMR1297 and Université Paul Sabatier, Toulouse, France

9 <sup>3</sup> Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago,  
10 IL, USA

11 \* **Correspondence:** [hperron@geneuro.com](mailto:hperron@geneuro.com); Hervé Perron, Geneuro-Innovation, Bioparc Laënnec,  
12 60A Avenue Rockefeller, 69008, Lyon, France. tel : +33 437 902 997

13 **Keywords:** long COVID-19, post-COVID-19, PASC, SARS-CoV-2, Immunoglobulin isotype,  
14 HERV-W, TLR4, cytokine, neurofilament, cognitive symptoms, brain fog.

15 Word count: 2741.

16

## 17 **Abstract**

18 Acute COVID-19 can cause a post-infectious syndrome in a significant percentage of patients, with  
19 multifacted and long lasting symptoms. We hypothesized that this Post-Acute COVID syndrome  
20 (PASC) could result from various underlying causes, which may compromise the demonstration of  
21 efficacy for treatments evaluated on cohorts of heterogeneous patients.

22 To assess the feasibility of stratifying or characterizing subgroups of post-COVID-19 patients  
23 consistent with different indications in a precision medicine perspective, we tested serum biomarkers  
24 in a pilot cross-sectional study of patients with neuro-cognitive symptoms from the Northwestern  
25 University post-COVID-19 clinic (Chicago,USA). Patient health status was evaluated with the use of  
26 standardized PROMIS questionnaires and underwent validated cognitive tests with the NIH Toolbox.  
27 Serum biomarkers were chosen as proteins known to be involved in the pathogenic features of a neuro-  
28 inflammatory disease, i.e., multiple sclerosis, with a final selection of the most discriminant ones. A  
29 multi-isotypes serology against SARS-CoV-2 spike and nucleocapsid antigens was performed to allow  
30 detailed analyses of the humoral immune status.

31 Despite the limited numbers of this feasibility study, results showed that clinical data could not  
32 differentiate PASC patients with persisting neuro-cognitive impairment, while three major PASC  
33 subgroups were identified with serum biomarkers according to the presence or absence of the HERV-  
34 W ENV soluble protein combined with neurofilaments light chains and, to a lesser extent, with elevated  
35 levels of IL-6. SARS-CoV-2 serological results in PASC compared to healthy controls also revealed a  
36 significant increase of anti-Spike and/or Nucleocapsid IgM, IgA and, unexpectedly, IgE. For IgG, a  
37 significant difference was observed with Nucleocapsid only since anti-Spike IgG titers were normally  
38 elevated in vaccinated controls. This multi-Ig isotypes serology may provide additional information on  
39 the infectious and immunological status of individual patients and should be considered in face of a  
40 potential viral persistence in some individuals.

41 Altogether the results show the feasibility of using serum biomarkers to discriminate relevant  
42 subgroups or individual patients for precision medicine indications in post-COVID syndromes. This  
43 pilot study paves the way to further exploring biological assays for the definition of subtypes of PASC,  
44 also called long COVID, useful for the choice of relevant therapeutic strategies.

45

## 46 **1 Introduction**

47 The COVID-19 pandemic is now known to generate a post-viral syndrome with multifaceted and long-  
48 lasting symptoms, variably named “Long COVID”, “Post-COVID” or “Post-Acute sequelae of  
49 COVID-19 (PASC). Though the last denomination may suggest lingering post-infectious symptoms,  
50 e.g., ischemic tissue lesions following thrombotic events <sup>1</sup>, many symptoms appear to result from  
51 ongoing pathogenic processes with possible onset of chronicity <sup>2,3</sup>.

52 In June 2022, the center for disease control (CDC) of the USA published that “more than 40% of adults  
53 in the United States reported having COVID-19 in the past, and nearly one in five of those (19%) are  
54 currently still having symptoms of long COVID”<sup>4</sup>. In September 2022, the World Health Organization  
55 (WHO) published that “at least 17 million people in the WHO European Region experienced long  
56 COVID in the first two years of the pandemic; millions may have to live with it for years to come” <sup>5</sup>.  
57 The data points to a secondary pandemic caused by COVID-19, in the form of a post-COVID syndrome  
58 of unknown duration and evolution with overlapping symptoms that may result from various  
59 pathogenic factors and pathways <sup>6</sup>. In particular, persisting neurological and cognitive symptoms  
60 appear common and affect the quality of life on the long term <sup>7,8</sup>.

61 Diagnosing and managing such a complex syndrome is a challenge that requires understanding how to  
62 identify potentially differing mechanisms underlying the overlapping symptoms observed in these  
63 patients <sup>9</sup>. There is a need to identify markers which will differentiate between heterogeneous long-  
64 COVID subgroups and guide precision medicine where possible. For this purpose, we have selected  
65 biomarkers from factors already known to be involved in COVID-19 and also suspected to contribute  
66 to certain aspects of long COVID or PACS. We also focused on assays suitable for routine laboratory  
67 analyses on serum samples, which can be easily obtained from patients.

68 In the present pilot study on patients from a post-COVID clinic presenting with persistent symptoms  
69 such as abnormal fatigue, sleep disorders and dominant neuro-cognitive symptoms, we have thus  
70 studied (i) immunoglobulin isotypes of the humoral response against SARS-CoV-2 spike and  
71 nucleocapsid antigens, (ii) the presence of an endogenous retroviral protein, HERV-W ENV, shown to  
72 be pathogenic for the immune and nervous systems <sup>10-12</sup>, with virus-induced expression <sup>13-15</sup> and  
73 recently shown to predict disease severity when detected on lymphocytes from COVID-19 patients <sup>16</sup>,  
74 (iii) the levels of major cytokines involved in COVID-19 inflammatory responses <sup>17</sup> and, because of  
75 neuro-cognitive symptoms, (iv) the levels of neurofilament light chain (NfL) known to be accurate  
76 biomarkers of neuronal impairment even when quantified in the peripheral blood <sup>18</sup>.

77

## 78 2 Methods

### 79 *Participants and clinical assessment*

80 This cross-sectional study was approved by the Northwestern University Institutional Review Board  
81 (STU00215866). Blood collection from patients and sample processing followed standard operating  
82 procedures with the appropriate approval of the Ethics and Scientific Committees (num.  
83 20210604/04/02). Written informed consent was obtained from all study participants. Importation of  
84 the human samples received the authorization IE-2022-2309 from the French ministry. Clinical and  
85 demographic data from PASC patients are presented in **Table 1**. PASC patient health status was  
86 evaluated with the use of standardized PROMIS questionnaires and underwent validated cognitive  
87 tests with the NIH Toolbox<sup>8,19,20</sup>.

### 88 *Immunoassays*

89 The detection of SARS-CoV-2 immunoglobulin isotypes (IgG, IgM, IgA and IgE) were performed on  
90 serum by Simple Western technology (ProteinSimple/BioTechne, CA, USA) with manufacturer's  
91 reagents according to their manual. HIS-tagged recombinant proteins of SARS-CoV-2 ((S)Spike, S1  
92 Subunit, S2 Subunit, S1 RBD and Nucleocapsid were used to detect antibody responses to SARS-CoV-  
93 2. The area under the curve (AUC) for the electrophoregram peak corresponding to the  
94 immunodetection of each protein at the expected size was measured using Compass Software.

95 For the detection of HERV-W ENV antigen in serum analyses were also performed with simple  
96 western-Jess, according to the conditions provided in the patent "Method for the detection of the  
97 soluble hydrophilic oligomeric form of HERV-W envelope protein", published under ref.  
98 WO2019201908, with previously described sample treatment (32). The specific signal was expressed  
99 as the signal to noise (S/N) ratio, where the noise represents the mean+2SD of the background signals  
100 yielded by a panel of sera from healthy blood donors (EFS, Lyon-France). PASC samples were stored  
101 in freezers at -80°C for less than 6 months. All samples were kept frozen after their initial freezing until  
102 use (no freeze/thaw cycle before the immunoassay).

103 Serum levels of NfL (# SPCKB-PS-002448) and IL-6 (# SPCKC-PS-006520) were quantified with  
104 the fully automated immunoassay platform, Ella (ProteinSimple/Bio-technie, CA, USA). The lower  
105 limits of quantification (LLOQ) were provided by the supplier as a threshold for normal baselines 3  
106 pg/mL for IL-6. Age-standardized Z-scores were calculated for NfLs {Harp, 2022 #18599}. Serum  
107 samples were run in triplicate and results in pg/mL were calculated by the instrument software  
108 (SimplePlex Explorer, ProteinSimple/Bio-technie, USA).

### 109 *RT-qPCR*

110 Total RNA was obtained from PAXgene tubes used to collect whole blood samples and stored at -  
111 20°C. RNA extraction used NucleoSpin RNA Mini Kit (Macherey Nagel, 740955) according to the  
112 manufacturer's protocol. 200 ng of DNase-treated RNA was reverse-transcribed into cDNA using  
113 iScript cDNA Synthesis Kit (Bio-Rad, 1708891) according to the manufacturer's protocol. A control  
114 with no-RT was used to confirm the absence of contaminating DNA. 5 ng of initial RNA in RT reaction  
115 was used in RT-qPCR for HERV-W *ENV*, HERV-W *POL*, HERV-K *ENV*, SARS-CoV-2 N genes.  
116 Primer sequences (5' to 3'): HERV-K ENV Forward CTGAGGCAATTGCAGGAGTT, Reverse  
117 GCTGTCTCTTCGGAGCTGTT; HERV-W ENV Forward GTATGTCTGATGGGGTGGAG,  
118 Reverse CTAGTCCTTTGTAGGGGCTAGAG; HERV-W POL Forward CCTGTACGTCCTGACTCTC,  
119 Reverse CTTGGGCTAATGCCTGGCC; SARS-CoV-2 N Forward AACATTCCCAACAG,

120 Reverse CACTGCTCATGGATTGTT; B2M Forward TTA CTCACGTCATTCAGCAG, Reverse  
121 GATGGATGAAACCCAGACAC. Assays used StepOnePlus instrument (Applied Biosystems) with  
122 Platinum SYBR Green (Invitrogen, 11744-500). Housekeeping gene beta-2 microglobulin (*B2M*)  
123 normalized the results. A melting curve analysis confirmed the specificity of amplification and the lack  
124 of non-specific products. Quantification used the threshold cycle (Ct) comparative method: the relative  
125 expression was calculated as follow:  $2^{-[DCt(\text{sample}) - DCt(\text{calibrator})]} = 2^{-DDCt}$ , where  $DCt(\text{sample}) = [Ct(\text{target}$   
126  $\text{gene}) - Ct(\text{housekeeping gene})]$  and the  $DCt(\text{calibrator})$  was the mean of  $DCt$  of healthy controls.

## 127 ***Statistics***

128 Statistical analyses were performed using Prism (version 9.0; GraphPad Software, La Jolla, California).  
129 Continuous data are expressed as means  $\pm$  SD, as indicated. Normal data distribution was assessed  
130 using the Shapiro-Wilk or D'Agostino & Pearson's test, assuming p-values  $> 0.05$ . Statistical  
131 differences were determined using Student's test (two tailed) for compared groups with normal  
132 distributions, with Welch's correction when SDs of samples were significantly different (F test  $p < 0.01$ )  
133 - Mann-Whitney U test (two tailed) was used for compared groups without normal distribution and  
134 Wilcoxon signed rank test (two tailed) was used for comparison when a group only or mostly  
135 comprised null or very low values for a given threshold. Chi-square (two tailed) test was used for  
136 comparison of numbers in categories, replaced by Fischer's exact test when one category had zero  
137 count. Correlation analyses were performed with Spearman test (two tailed). Statistical significance  
138 was set at  $p < 0.05$ .

139

### 140 3 Results

141 A total of 41 subjects (Table 1) were evaluated in this study. Controls (Ctrl) were caregivers or  
142 volunteers from hospital (n=10) and PASC patients previously diagnosed with acute COVID-19 and  
143 presenting with neuro-cognitive symptoms, (Neuro-PASC; n=31). These included 6 post-  
144 hospitalization Neuro-PASC (PNP) and 25 non-hospitalized Neuro-PASC (NNP) patients seen at  
145 Northwestern Medicine Neuro-COVID-19 clinic.

#### 146 *HERV-W ENV detection*

147 Following reports of HERV-W envelope RNA and protein in acute COVID-19 patients correlating  
148 with disease severity and markers of T-cell exhaustion<sup>16</sup>, this study analyzed HERV-W *ENV* RNA  
149 from whole blood and levels of soluble envelope protein (W-ENV) in serum from PASC compared to  
150 Ctrl. As shown in Figure 1 A-D, about one-half (11/23 with QC-passed RNA) of PASC individuals  
151 had elevated RNA levels and about one-third (10/31) had detectable W-ENV protein in serum, which  
152 was significantly different from Ctrl for both analyses (Wilcoxon Signed Rank test: Ctrl W=1.00,  
153 PASC W=177.00, N=7+23, p=0.0055 for whole blood RNA, and Ctrl W=10.00, PASC W=265.00,  
154 N=10+31, p=0.0020 for serum protein). RT-qPCR also detects non-coding RNA and it is known that  
155 HERV RNA could play physiological roles as regulatory non-coding long or small RNA<sup>21,22</sup>.  
156 Nevertheless, the presence of circulating W-ENV protein, a potent TLR4 agonist, cannot be neutral<sup>12,23-  
157 26</sup>.

158 In Figure 1C PASC patients were stratified based on hospitalization status during acute SARS-CoV-2  
159 infection. Positive cases for W-ENV protein represented about one fourth in the NNP subgroup (24%,  
160 6/25), but a majority in the PNP subgroup (67%, 4/6). The difference of W-ENV signal to noise values  
161 (S/N) between NNP and controls was significant (Wilcoxon Signed Rank test: Ctrl W=1.00, PASC  
162 W=21.00, N=10+25, p=0.0313) but, probably due to the low numbers, not between PNP and Ctrl.  
163 Interestingly, W-ENV positive (W-ENV+) PASC patients tended to be further from the date of  
164 infection (Fig. 1D). A significant difference in the time from onset of acute COVID-19 between W-  
165 ENV+ and W-ENV- patients was confirmed (Unpaired t-test with Welch's correction: t=2,346,  
166 df=17,61, N=21+10, p=0.0309). Some of these cases had suffered from post-COVID symptoms for  
167 two years after the acute infection, which corresponded to the beginning of the pandemic.

168

#### 169 *SARS-CoV-2 -specific antibody responses*

170 To study the humoral immune response to SARS-CoV-2 infection in PASC patients, we measured the  
171 levels of all immunoglobulins (IgG, IgM, IgA and IgE) versus the control group (including vaccinated  
172 individuals) against SARS-CoV-2 nucleocapsid (N) and spike (S) antigens.

173 Anti-N IgG were detected in a subgroup of PASC patients but not in controls (Wilcoxon Signed Rank  
174 test: Ctrl W=0.00, PASC W=444.0, N=10+31, p<0.0001; Fig. 1E), whereas no difference with Ctrl  
175 was observed for the anti-S IgG (Fig. 1F), which mostly indicated that Ctrl had been vaccinated with  
176 this antigen. Comparing W-ENV positive and negative PASC patients showed that anti-N IgG  
177 antibodies were detected in both subgroups, each one remaining significantly different from Ctrl  
178 (Wilcoxon Signed Rank test: Ctrl W=0.00, PASC/W-ENV- W=193.0, N=10+21, p=0.0003; Ctrl  
179 W=0.00, PASC/W-ENV+ W=53.0, N=10+10, p=0.0039; Fig. 1G), but no difference was seen between  
180 PASC subgroups and Ctrl for anti-spike IgG (Fig. 1H).

181 As shown in Figure 2, IgM against both S and N proteins were only observed in a subgroup of PASC  
182 patients with a wide range of titers. But, despite a few IgM positive PASC cases, a significant difference

183 was seen versus controls for anti-N IgM (Wilcoxon Signed Rank test: Ctrl W=1600, PASC W=476.0,  
184 N=10+31 p=0.0480; Fig. 2 A) and, with high significance, for anti-S IgM (Wilcoxon Signed Rank test:  
185 Ctrl W=-6.00, PASC W=183.0, N=10+29, p<0.0001; Fig. 2 B). Of note, two sera with non interpretable  
186 technical profiles were omitted.. IgA antibodies levels were shown to be significantly elevated in PASC  
187 versus Ctrl for both N and S antigens, but anti-N IgA better discriminated PASC versus Ctrl (Wilcoxon  
188 Signed Rank test: anti-N IgA, Ctrl W=16.00, PASC W=476.0, N=10+31 p<0.0001; anti-S IgA, Ctrl  
189 W=-2.00, PASC W=273.0, N=10+31 p=0.0063; Fig. 2 C-D). Surprisingly, a subgroup of PASC  
190 patients had elevated IgE immunoglobulins against both N and S antigens (Wilcoxon Signed Rank test:  
191 anti-N IgE, Ctrl W=5.00, PASC W=336.0, N=10+31 p=0.0006; anti-S IgE, Ctrl W=14.00, PASC  
192 W=456.0, N=10+31 p<0.0001 ), with a large range of positivity versus all negative controls (Fig. 2 E-  
193 F).

#### 194 ***IL-6 quantification***

195 IL-6 was suggested to play a role in acute COVID-19 severity. In PASC, only a subgroup had elevated  
196 IL-6 (about 35%, 11/31) but, whereas most values were below the normal threshold (3pg/ml) in NNP,  
197 nearly all PNP (5/6) had elevated IL-6 levels in the serum with a significant difference from Ctrl (Mann  
198 Whitney test: U=3, N=10+6, p=0.0017; Fig. 3A). When W-ENV positive and negative PASC  
199 subgroups were compared, the W-ENV+ patients showed significantly higher IL-6 levels (Mann  
200 Whitney test: U=31, N=21+10, p=0.0011; Fig. 3B), consistently with the significant correlation found  
201 between PASC serum levels of HERV-W ENV and IL-6 (Spearman correlation test: r=0.5877, 95%  
202 CI 0.2847 to 0.7840, pairs N=31, p=0.0005; Fig. 3C). In figure 3D, PASC were stratified according to  
203 both anti-N SARS-CoV-2 IgG and W-ENV serum levels. All samples from the W-ENV+ subgroup  
204 had elevated IL-6 levels, when compared to all other W-ENV negative sera with or without anti-N IgG  
205 (Mann Whitney test: W-ENV+/IgG N+ Vs W-ENV-/IgG N-, U=7, N=8+9, p=0.0035; W-ENV+/IgG  
206 N+ Vs W-ENV-/IgG N+, U=10, N=8+13, p=0.0013; Fig. 3D).

#### 207 ***Neuronal impairment biomarker: Neurofilament Light chain (NfL)***

208 We measured the levels of serum NfL in PASC with cognitive impairment, since shown to be an  
209 accurate peripheral biomarker of neuronal degeneration or injury within the central nervous system<sup>27</sup>  
210 (Figure 3E-G). Results were normalized with Z-score according to the age of the patients or control  
211 individuals, as already defined<sup>28</sup>.

212 No significant difference was found between the distributions of NfL serum levels in PNP versus NNP,  
213 nor Vs Ctrl (Fig. 3 E). Nonetheless, when stratified with W-ENV, all (100%, 10/10) W-ENV+ patients  
214 had elevated levels of serum NfL while only 62% (13 out of 21) of W-ENV-negative sera had a NfL  
215 Z-scores above 0 (Fisher exact test = 0.0317 p<0.05,  $\alpha=1$ , N=31; Fig. 3 F). Moreover, Z-scores were  
216 all above zero in the subgroup with both W-ENV and anti-N IgG positivity which was significantly  
217 different from the anti-N IgG+ and W-ENV- subgroup (Unpaired t test with Welch's correction:  
218 t=2,688, df=17,61, N=22, p= 0,0152; Fig. 3G),.

#### 219 ***Biomarker-defined subgroups***

220 Figure 3H represents clusters of all PASC patients studied for the above-mentioned serum biomarkers.  
221 Within the W-ENV+ subgroup the majority (7/10) of PASC were positive altogether for NfL, IL-6 and  
222 IgG anti N-SARS-CoV-2 but only one (1/21) in the W-ENV negative subgroup (Chi-square  
223 statistic=17.890, p=0.00002,  $\alpha=1$ , N=31 tested on all parameters). All W-ENV+ Neuro-PASC had  
224 positive serum levels of NfL (10/10). Moreover, within the W-ENV + subgroup, the NfL+ cluster  
225 included all IL-6+ or Ig anti-N+ sera and therefore coincided with W-ENV positivity in Neuro-PASC  
226 patients, i.e., defined the same subgroup when combined with W-ENV positivity. Matching with acute  
227 COVID effective hospitalization also, all HERV-W ENV+ patients from the PNP subgroup were  
228 positive for the three other biomarkers (NfL, IL-6 and IgG anti-N; data not shown).

229 Within the W-ENV- subgroup, a single case was positive for NfL, IL-6 and IgG anti-N altogether. As  
230 found to be the core parameters in the W-ENV+ subgroup, this may question the sensitivity of the  
231 present test for HERV-W ENV soluble antigen detection in serum. The patterns for single or double  
232 positivity appeared to be variable while only NfLs positive levels were dominant, thereby suggesting  
233 relationship with the neuro-cognitive impairment in this cohort. However, a cluster was clearly  
234 identified to be negative for all these biomarkers, beyond negativity for W-ENV as well. This “all  
235 negative” cluster is consistent with very different pathogenic factors involved in their post-COVID  
236 symptomatology.

237 Of note, though all W-ENV+ patients had positive Z-scores for NfL, taken alone this biomarker  
238 revealed dominant in all Neuro-PASC cases, W-ENV+ and W-ENV- (Figure 3F). Negative Z-scores  
239 were found in few cases positive for IL-6 only or for IgG anti-N only but, most interestingly, within  
240 the isolated cluster negative for all tested biomarkers (figure 3H).

241 SARS-CoV-2 serology showed significant differences with controls for anti-N IgG (Figure 1E) and  
242 for anti-N and/or anti-S IgM, IgA or IgE (Figures 2A-F). But, even in combination with other  
243 biomarkers, it did not provide a clear-cut stratification when considered without the other studied  
244 biomarkers.

245 Therefore, Neuro-PASC subgroups could be defined as (i) W-ENV+ and NfL+, (ii) W-ENV- and  
246 (NfL+ or IL-6+ or IgG anti-N+) and (iii) negative for all the tested parameters. In addition, possible  
247 indication may be also provided on SARS-CoV-2 persistence by IgM, on the route of infection in  
248 extrapulmonary cases<sup>29</sup> or on the site of persistence by IgA and, particularly, on potentially associated  
249 immunoallergic symptoms by IgE.

250 Finally, using data from the PROMIS scale<sup>30</sup> and other clinical data showed no significant difference  
251 in the distribution of results between the subgroups consistently defined by the different biomarkers as  
252 exemplified with HERV-W ENV and anti-N-SARS-CoV-2 IgG in Figure 4.

253



## 254 **Conclusion**

255 The present results, despite the limited number of patients, consistently identified three major Neuro-  
256 PASC subgroups with significant differences stratified according to the presence or absence of the  
257 HERV-W ENV protein combined with positive Z-score for NfLs in serum. SARS-CoV-2 serology  
258 with all Ig isotypes should also provide useful indications on the infectious status, with possible viral  
259 persistence or a possible immunoallergic specific phenotype linked to elevated anti-spike or  
260 Nucleocapsid IgE. Since clinical data could not differentiate consistent subgroups of patients, unlike  
261 biological parameters, the biomarker-defined subgroups or clusters may be considered for differing  
262 therapeutic indications in post-COVID treatment. This should be a prerequisite for clinical trials to  
263 avoid mixing patients with and without the pathogenic target of a given drug, which may generate non-  
264 significant results versus placebo, despite possibly responding cases. Thus, the presented biomarker  
265 and serology-based stratification should pave the way to precision medicine in post-acute COVID  
266 sequelae or syndromes. Based on the present proof of concept and on that of other studies , a diagnostic-  
267 based therapy with an anti-HERV-W ENV neutralizing antibody (Temelimab) is being evaluated in a  
268 clinical trial with PASC patients positive for the HERV-W ENV protein in serum (NCT ).

## 269 Figure Legends

270

271 **Figure 1. HERV-W ENV and Anti-Nucleocapsid IgG antibody are significantly detected in PASC.** A, HERV-W  
272 *ENV* mRNA detection in PBMCs based on change fold of  $2^{-\Delta\Delta CT}$  compared to the mean of control groups; blue dots: controls  
273 group; red dots: PASC group. Here, a lower number of samples was analyzed, since 8 PASC and 3 controls yielded too  
274 low RNA concentration or did not pass QC (RIN<8). B, HERV-W ENV soluble oligomeric protein detection in serum of  
275 patients, results are expressed on total signal normalized with the mean of background noise measured on control cohort;  
276 blue dots : controls group; red dots : PASC group. C, post-hospitalized subgroup (PNP) is extracted from the PASC group  
277 and compared to PASC subgroup not hospitalized during acute COVID-19 (NNP); blue dots: controls group; red dots: NNP  
278 subgroup; dark red dots: PNP sub group. D, Comparison of the time from onset between HERV-W ENV- and HERV-W  
279 ENV+ PASC subgroups; grey dots: PASC HERV-W ENV- subgroup; orange dots: PASC HERV-W ENV+ subgroup. E,  
280 IgG anti-SARS-CoV-2 Nucleocapsid; F, IgG anti-SARS-CoV-2 Spike. Comparison between PASC HERV-W ENV- and  
281 PASC HERV-W ENV+ subgroups for IgG anti-Nucleocapsid (G), and anti-Spike (H). The value on the Y-axis (U)  
282 represents the area under the curve (AUC) of the electrophoregram specific peak corresponding to the immunodetected Ig  
283 isotype from tested sera against each antigen.

284 **Figure 2. PASC serological IgM, IgA and IgE.** A, IgM anti-SARS-CoV-2 Nucleocapsid; B, IgM anti-SARS-CoV-2  
285 Spike IgM anti-S and N of two PASC patients with inconsistent results and diverging triplicate values were not be  
286 interpretable and therefore not taken into account in this analysis.; C, IgA anti-SARS-CoV-2 Nucleocapsid; D, IgA anti-  
287 SARS-CoV-2 Spike; E, IgE anti-SARS-CoV-2 Nucleocapsid and F, IgE anti-SARS-CoV-2 Spike. The value on Y axis (U)  
288 represents the area under the curve (AUC) of the electrophoregram specific peak corresponding to the immunodetected Ig  
289 isotype from tested sera against each antigen.

290 **Figure 3. Interleukine-6 (IL-6), neurofilament light chain (NfL) biomarkers and combination with HERV-W ENV  
291 or anti-nucleocapsid IgG (IgG anti-N) status stratifying PASC patients.** A, IL-6 dosages for controls (bleu dots), NNP  
292 (red dots) and PNP (dark red dots). B, IL-6 dosage comparisons between HERV-W ENV- and HERV-W ENV+ subgroups  
293 in PASC cohort. C, correlation between IL-6 and HERV-W ENV levels in serum. D, IL-6 levels in PASC patients stratified  
294 by: HERV-W ENV- / IgG anti-N- (grey dots), HERV-W ENV- / IgG anti-N+ (blue dots) and HERV-W ENV+ / IgG anti-  
295 N+ (red dots). E, NfL Z-Scores of controls (blue dots), NNP (red dots) and PNP (dark red dots). NfL Z-scores comparisons  
296 between HERV-W ENV- and HERV-W ENV+ subgroups in PASC cohort. G, NfL levels in different PASC subgroups:  
297 HERV-W ENV- / IgG anti-N- (grey dots), HERV-W ENV- / IgG anti-N+ (blue dots) and HERV-W ENV+ / IgG anti-N+  
298 (red dots). H, Graphical presentation of patients' clusters defined by the selected serum biomarkers, within HERV-W ENV  
299 negative and HERV-W ENV positive subgroups. The sera positive for each biomarker are represented by dots in the colored  
300 circles; those negative for all parameters are in the grey oval.

301 **Figure 4. Comparison of clinical data between groups based on HERV-W ENV and serology profiles.** Three groups  
302 from the PASC cohort are represented based on main biomarkers results: HERV-W ENV+ /Igs anti-SARS-CoV-2  
303 Nucleocapsid (Ig anti-N) + ; HERV-W ENV- /Igs anti-SARS-CoV-2 Nucleocapsid (Ig anti-N) + and HERV-W ENV- /Igs  
304 anti-SARS-CoV-2 Nucleocapsid (Ig anti-N). Several parameters were studied: A, Processing speed; B, Attention; C,  
305 Executive function; D, Working Memory; E, Cognitive function; F, Fatigue; G, Anxiety; H, Depression and I, Recovery  
306 compared to the baseline.

307

308 **Conflict of Interest**

309 *HP, BC, JB and BC receive compensation from Geneuro-Innovation for their work. The other authors*  
310 *declare that the research was conducted in the absence of any commercial or financial relationships*  
311 *that could be construed as a potential conflict of interest.*

312

313 **Author Contributions**

314 IK : conceptualization of the study, evaluating all patients in the Neuro-COVID-19 clinic,  
315 supervising patients sample collection, manuscript editing and review

316 NW collaborators: Zack and Millenia: organized sample and data collection from all Neuro-PASC  
317 and control patients at Northwestern University, manuscript review

318 Barbara and Lavanya: Conceptualization of the study, assisted in sample and data collection from all  
319 Neuro-PASC and control patients at Northwestern University, editing and reviewing the manuscript

320 HP: conceptualization, supervision, formal analysis, investigation, data curation, writing and  
321 manuscript review.

322 AL, CB, SF: HERV-W-ENV detection, NfL, cytokines HERV-W-ENV detection, NfL, cytokines,  
323 serological analyses.

324 B.C.: methodology, management interpretation of analyses and manuscript review.

325 J.P: Serological and antigenemia analyses; graphs, figures drawing and manuscript review.

326 J.B.: PCR, serological and antigenemia analyses; graphs, figures drawing and manuscript review.

327 H.P. and E.O.: conceptualization, funding acquisition, supervision, formal analysis, investigation, data  
328 curation, writing original draft and manuscript review.

329 All authors contributed to the article and approved the submitted version.

330

331

## 332 References

333

334 1. Hamouda D, Jillella DV, Bhatt N, Koneru S, Frankel MR, Nogueira RG. Intraluminal carotid  
335 thrombosis and acute ischemic stroke associated with COVID-19. *J Neurol*. Dec 2021;268(12):4443-  
336 4447. doi:10.1007/s00415-021-10562-1

337 2. Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy-  
338 associated morbidity in Covid-19 patients. *Ann Clin Transl Neurol*. Nov 2020;7(11):2221-2230.  
339 doi:10.1002/acn3.51210

340 3. Nehme M, Braillard O, Chappuis F, CoviCare Study T, Guessous I. The chronification of post-  
341 COVID condition associated with neurocognitive symptoms, functional impairment and increased  
342 healthcare utilization. *Sci Rep*. Aug 25 2022;12(1):14505. doi:10.1038/s41598-022-18673-z

343 4. CDC. *Prevalence of long COVID in the USA*. 2022.

344 5. WHO. *Long COVID in the WHO European Region*. 2022.

345 6. Global Burden of Disease Long CC, Wulf Hanson S, Abbafati C, et al. Estimated Global  
346 Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters  
347 Following Symptomatic COVID-19 in 2020 and 2021. *JAMA*. Oct 25 2022;328(16):1604-1615.  
348 doi:10.1001/jama.2022.18931

349 7. Ali ST, Kang AK, Patel TR, et al. Evolution of neurologic symptoms in non-hospitalized  
350 COVID-19 "long haulers". *Ann Clin Transl Neurol*. Jul 2022;9(7):950-961. doi:10.1002/acn3.51570

351 8. Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive  
352 dysfunction in non-hospitalized Covid-19 "long haulers". *Ann Clin Transl Neurol*. May  
353 2021;8(5):1073-1085. doi:10.1002/acn3.51350

354 9. O'Hare AM, Vig EK, Iwashyna TJ, et al. Complexity and Challenges of the Clinical Diagnosis  
355 and Management of Long COVID. *JAMA Netw Open*. Nov 1 2022;5(11):e2240332.  
356 doi:10.1001/jamanetworkopen.2022.40332

357 10. Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN. The envelope protein  
358 of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and  
359 promotes Th1-like responses. *J Immunol*. Jun 15 2006;176(12):7636-44.

360 11. Firouzi R, Rolland A, Michel M, et al. Multiple sclerosis-associated retrovirus particles cause  
361 T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. *J Neurovirol*.  
362 Feb 2003;9(1):79-93. doi:10.1080/13550280390173328

363 MN2N2T34QVXHRWNY [pii]

364 12. Kremer D, Gruchot J, Weyers V, et al. pHERV-W envelope protein fuels microglial cell-  
365 dependent damage of myelinated axons in multiple sclerosis. *Proc Natl Acad Sci U S A*. Jul 23  
366 2019;116(30):15216-15225. doi:10.1073/pnas.1901283116


367 13. Ruprecht K, Obojes K, Wengel V, et al. Regulation of human endogenous retrovirus W protein  
368 expression by herpes simplex virus type 1: implications for multiple sclerosis. *J Neurovirol*. Feb  
369 2006;12(1):65-71. doi:T6G5G8M106986441 [pii]

370 10.1080/13550280600614973

- 371 14. Charvet B, Reynaud JM, Gourru-Lesimple G, Perron H, Marche PN, Horvat B. Induction of  
372 Proinflammatory Multiple Sclerosis-Associated Retrovirus Envelope Protein by Human Herpesvirus-  
373 6A and CD46 Receptor Engagement. *Front Immunol.* 2018;9:2803. doi:10.3389/fimmu.2018.02803
- 374 15. Li F, Nellaker C, Sabunciyan S, et al. Transcriptional derepression of the ERVWE1 locus  
375 following influenza A virus infection. *J Virol.* Apr 2014;88(8):4328-37. doi:10.1128/JVI.03628-13
- 376 16. Balestrieri E, Minutolo A, Petrone V, et al. Evidence of the pathogenic HERV-W envelope  
377 expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients.  
378 *EBioMedicine.* Apr 2021;66:103341. doi:10.1016/j.ebiom.2021.103341
- 379 17. Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV-  
380 2. *Nat Immunol.* Feb 2022;23(2):165-176. doi:10.1038/s41590-021-01091-0
- 381 18. Fisse AL, Pitarokoili K, Leppert D, et al. Serum neurofilament light chain as outcome marker  
382 for intensive care unit patients. *J Neurol.* Apr 2021;268(4):1323-1329. doi:10.1007/s00415-020-  
383 10277-9
- 384 19. Lai JS, Wagner LI, Jacobsen PB, Cella D. Self-reported cognitive concerns and abilities: two  
385 sides of one coin? *Psychooncology.* Oct 2014;23(10):1133-41. doi:10.1002/pon.3522
- 386 20. Lai JS, Cella D, Choi S, et al. How item banks and their application can influence measurement  
387 practice in rehabilitation medicine: a PROMIS fatigue item bank example. *Arch Phys Med Rehabil.*  
388 Oct 2011;92(10 Suppl):S20-7. doi:10.1016/j.apmr.2010.08.033
- 389 21. Wilson KD, Ameen M, Guo H, et al. Endogenous Retrovirus-Derived lncRNA BANCR  
390 Promotes Cardiomyocyte Migration in Humans and Non-human Primates. *Dev Cell.* Sep 28  
391 2020;54(6):694-709 e9. doi:10.1016/j.devcel.2020.07.006
- 392 22. Chishima T, Iwakiri J, Hamada M. Identification of Transposable Elements Contributing to  
393 Tissue-Specific Expression of Long Non-Coding RNAs. *Genes (Basel).* Jan 9  
394 2018;9(1)doi:10.3390/genes9010023
- 395 23. Johansson EM, Bouchet D, Tamouza R, et al. Human endogenous retroviral protein triggers  
396 deficit in glutamate synapse maturation and behaviors associated with psychosis. *Science Advances.*  
397 2020;6(29):eabc0708. doi:10.1126/sciadv.abc0708
- 398 24. Madeira A, Burgelin I, Perron H, Curtin F, Lang AB, Faucard R. MSRV envelope protein is a  
399 potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in  
400 multiple sclerosis treatment. *J Neuroimmunol.* Feb 15 2016;291:29-38.  
401 doi:10.1016/j.jneuroim.2015.12.006
- 402 25. Duperray A, Barbe D, Raguenez G, et al. Inflammatory response of endothelial cells to a human  
403 endogenous retrovirus associated with multiple sclerosis is mediated by TLR4. *Int Immunol.* Nov  
404 2015;27(11):545-53. doi:10.1093/intimm/dxv025
- 405 26. Kremer D, Schichel T, Forster M, et al. Human endogenous retrovirus type W envelope protein  
406 inhibits oligodendroglial precursor cell differentiation. *Ann Neurol.* Nov 2013;74(5):721-32.  
407 doi:10.1002/ana.23970
- 408 27. Chitnis T, Gonzalez C, Healy BC, et al. Neurofilament light chain serum levels correlate with  
409 10-year MRI outcomes in multiple sclerosis. *Ann Clin Transl Neurol.* Dec 2018;5(12):1478-1491.  
410 doi:10.1002/acn3.638
- 411 28. Harp C, Thanei GA, Jia X, et al. Development of an age-adjusted model for blood  
412 neurofilament light chain. *Ann Clin Transl Neurol.* Apr 2022;9(4):444-453. doi:10.1002/acn3.51524

- 413 29. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat*  
414 *Med.* Jul 2020;26(7):1017-1032. doi:10.1038/s41591-020-0968-3
- 415 30. Vartanian K, Fish D, Gronowski B, Kenton N, Robicsek A. Patient-Reported Outcomes for  
416 Fully Vaccinated COVID-19 Patients Over 6 Weeks: The Experiences of Clinical Breakthrough Cases.  
417 *Patient.* Nov 7 2022:1-12. doi:10.1007/s40271-022-00605-8
- 418

Figure 1



IgG anti-SARS-CoV-2 Nucleocapsid      IgG anti-SARS-CoV-2 Spike







Figure 3



**Figure 4**

medRxiv preprint doi: <https://doi.org/10.1101/2023.03.31.23288003>; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

